Multiple Myeloma (MM) affects over 130,000 people in the US. This year alone (2020), 3,000 and 32,000 people living in Canada and the US, respectively, are expected to be newly diagnosed with MM. In MM, abnormal antibody-producing plasma cells clonally expand and accumulate in the bone marrow. Malignant plasma cells often secrete an antibody, called myeloma (M)-protein, which can be detected in the blood and/or urine of most MM patients.
In MM, aberrant plasma cells reside in the bone marrow, with only a fraction circulating in the bloodstream. In contrast, the abnormal antibody (M-protein) is secreted into the blood for the majority of MM patients, making it an ideal biomarker to track disease status. Our protein sequencing technology is perfectly suited to retrieve a patient’s specific M-protein’s sequence information to easily monitor patient status from diagnosis through treatment and remission.
MM is known as a relapsing-remitting cancer and research has shown that earlier detection results in a better prognosis. As such, detecting relapse early can prevent delays in treatment. Rapid Novor’s team is dedicated to helping patients and clinicians reach early detection of relapse for improved prognosis and treatment. Empowered by our proven de novo antibody protein sequencing technology, EasyM™ is sensitive, patient-friendly, and personalized, allowing clinicians to easily monitor each patient for a better quality of life.
Committed to engaging in clinical development, patient care, and raising awareness, we have partnered with Myeloma Canada, and are actively involved in fundraising for, and collaborating with the Myeloma community. In 2018, our team was awarded 2nd place for fundraising in the Canadian Multiple Myeloma March. We recently completed a retrospective clinical trial in collaboration with a large Canadian center, and are undergoing a larger clinical trial with a high-profile US hospital. With EasyM™, we hope to improve clinical outcomes for those living with MM by ensuring earlier relapse detection.